Panel backs Celebrex for juvenile arthritis
(Reuters)


Reuters - Pfizer Inc.'s pain
reliever Celebrex should be approved for treating rheumatoid
arthritis in children despite uncertainty about the risks of
long-term use, U.S. advisers said on Wednesday.